NCT01153360

Brief Summary

This study is planned to medicate oral T3(Liothyronine)to the patients who are planned to have OPCAB(off- pump coronary bypass graft surgery. The aim of this study was to assess the effects of oral triiodothyronine (T3) therapy on postoperative thyroid hormone concentrations, hemodynamic variables and outcomes in patients undergoing OPCAB in a randomized, controlled trial.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
100

participants targeted

Target at P50-P75 for not_applicable

Timeline
Completed

Started Jun 2010

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

June 1, 2010

Completed
28 days until next milestone

First Submitted

Initial submission to the registry

June 29, 2010

Completed
1 day until next milestone

First Posted

Study publicly available on registry

June 30, 2010

Completed
1.1 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

August 1, 2011

Completed
1 month until next milestone

Study Completion

Last participant's last visit for all outcomes

September 1, 2011

Completed
Last Updated

July 24, 2012

Status Verified

July 1, 2012

Enrollment Period

1.2 years

First QC Date

June 29, 2010

Last Update Submit

July 23, 2012

Conditions

Outcome Measures

Primary Outcomes (1)

  • compare the serum T3 concentrations and the number of patients with serum T3 concentrations below the normal range between the groups

    until 36 hours after surgery

Secondary Outcomes (1)

  • difference of hemodynamic performance and myocardial injury

    during surgery and 36 hr after surgery

Other Outcomes (1)

  • major morbidity endpoints including acute renal failure, cardiovascular failure, stroke, mediastinitis, need for ventilator support for >48 h, and new onset atrial fibrillation

    until discharge of hospital

Study Arms (2)

T3

EXPERIMENTAL

triiodothyronine

Drug: liothyronine sodium

cyanocobalamin

ACTIVE COMPARATOR

vitamin B12

Drug: placebo

Interventions

liothyronine sodium 20ug, every 12hour (before anesthetic induction, total 4 times)

T3

vitamin B12

cyanocobalamin

Eligibility Criteria

Age20 Years - 75 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Patients who are undergoing Off-pump coronary artery bypass graft

You may not qualify if:

  • No normal sinus rhythm,
  • History of thyroid disease
  • Abnormal thyroid hormone
  • Renal dysfunction
  • Hepatic dysfunction
  • LVEF \<30%
  • Recent MI
  • Active infection 1\~15

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Severance Hospital

Seoul, South Korea

Location

MeSH Terms

Conditions

Euthyroid Sick Syndromes

Interventions

Triiodothyronine

Condition Hierarchy (Ancestors)

Thyroid DiseasesEndocrine System Diseases

Intervention Hierarchy (Ancestors)

ThyroninesThyroid HormonesHormonesHormones, Hormone Substitutes, and Hormone AntagonistsThyroxineAmino Acids, AromaticAmino Acids, CyclicAmino AcidsAmino Acids, Peptides, and Proteins

Study Officials

  • Yong-Sun Choi, MD, Ph.D

    Anesthesiology & Pain Medicine, Severance Hospital

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
DOUBLE
Who Masked
PARTICIPANT, INVESTIGATOR
Purpose
SUPPORTIVE CARE
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
assistant professor

Study Record Dates

First Submitted

June 29, 2010

First Posted

June 30, 2010

Study Start

June 1, 2010

Primary Completion

August 1, 2011

Study Completion

September 1, 2011

Last Updated

July 24, 2012

Record last verified: 2012-07

Locations